Moderna experienced a significant 20% drop in its stock price on Thursday after reporting second-quarter results that, while beating revenue expectations, prompted the company to sharply...
Etiket: cost-cutting
Biogen Surpasses Q2 Expectations and Raises Outlook as Alzheimer’s Drug Leqembi and New Products Drive Growth
Biogen reported second-quarter earnings and revenue that exceeded estimates, leading to an increase in the company’s full-year guidance. The improved outlook is attributed to the successful...